Akebia Therapeutics (AKBA) Return on Equity (2014 - 2026)

Akebia Therapeutics (AKBA) has 13 years of Return on Equity data on file, last reported at 0.01% in Q1 2026.

• Return on Equity for Q1 2026 came in at 0.01%, down 4.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (down 4.0% YoY), and the FY2025 annual result was 0.01%, down 1.0% from the prior year.
• Return on Equity slipped to 0.01% in Q1 2026 per AKBA's latest filing, from 0.0% in the prior quarter.
• Over five years, Return on Equity peaked at 0.08% in Q1 2023 and troughed at 0.14% in Q4 2022.
• A 5-year average of 0.0% and a median of 0.01% in 2024 frame the typical range for Return on Equity.
• The sharpest annual moves came in 2022 and 2023: Return on Equity decreased 12 bps in 2022, then climbed 16 bps in 2023.
• A 5-year view of Return on Equity shows it stood at 0.14% in 2022, then surged by 110 bps to 0.01% in 2023, then declined by 6 bps to 0.01% in 2024, then plunged by 110 bps to 0.0% in 2025, then sank by 375 bps to 0.01% in 2026.
• Business Quant data shows AKBA's Return on Equity at 0.01% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.